多模态肺部成像:使用来自 CT 和超极化 ¹²⁹Xe MRI 的互补信息评估肺结构-功能

Executive Industry Relevance

Integrating hyperpolarized ¹²⁹Xe MRI with CT imaging enables comprehensive evaluation of lung structure and function, supporting advanced target validation and mechanistic de-risking in respiratory drug discovery. This multi-modal approach enhances predictive confidence at key inflection points in pulmonary R&D pipelines, facilitating risk-adjusted portfolio decisions for novel therapeutics targeting lung disease. The method's quantitative and regional outputs position it as a strategic asset for translational research and preclinical model development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of regional lung structure-function relationships for mechanistic de-risking.
• Supports functional target validation by correlating imaging biomarkers with disease-relevant phenotypes.
• Facilitates predictive confidence in early-stage respiratory asset triage.

Screening & Assay Development

• Prepares validated imaging-based assays for quantitative evaluation of pulmonary interventions.
• Standardizes regional lung function measurements for reproducibility across studies.
• Enables scalable, platform-ready workflows for compound screening in disease-relevant systems.

Translational & Preclinical Research

• Aligns imaging biomarkers with translational endpoints for preclinical model validation.
• Provides continuity from discovery through preclinical assessment of lung-targeted therapies.
• Supports risk-adjusted advancement by quantifying structure-function changes in disease models.

Pipeline & Workflow Integration

This multi-modal imaging protocol bridges early discovery, lead identification, and preclinical validation in respiratory R&D workflows.

• Discovery Biology: Quantitative structure-function mapping informs hypothesis testing and pathway clarification.
• Screening: Imaging-based assays deliver reproducible, regional readouts for compound evaluation.
• Analytics: Registration outputs enable direct comparison of structural and functional lung metrics.
• Translational Research: Imaging endpoints support biomarker alignment and preclinical model continuity.
• Enterprise Reuse: The protocol is adaptable across respiratory models and supports cross-program standardization.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in lung disease research.
• Operational Value: Delivers standardized, reproducible imaging workflows for multi-site studies.
• Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust target validation.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory assets.

Implementation Considerations

• Requires expertise in advanced imaging modalities and image registration techniques.
• Demands access to CT and hyperpolarized ¹²⁹Xe MRI instrumentation and computational infrastructure.
• Necessitates cross-team standardization of imaging protocols and data formats.
• Adaptation may be needed for different lung disease models or imaging platforms.
• Technical challenges in image registration and alignment must be addressed for consistent outputs.

Biopharma FAQs